Article
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Gastroenterology - 1 Jul 2014
Di Bisceglie Adrian M, Janczweska-Kazek Ewa, Habersetzer François, Mazur Wlodzimierz, Stanciu Carol, Carreno Vicente, Tanasescu Coman, Flisiak Robert, Romero-Gomez Manuel, Fich Alexander, Bataille Vincent, Toh Myew-Ling, Hennequi Marie, Zerr Patricia, Honnet Géraldine, Inchauspé Geneviève, Agathon Delphine, Limacher Jean-Marc, Wedemeyer Heiner
Abstract excerpt
BACKGROUND & AIMS: TG4040 is a modified vaccinia Ankara (MVA) virus that expresses the hepatitis C virus (HCV) proteins NS3, NS4, and NS5B. We performed a phase II open-label study to determine the efficacy, safety, and immunotherapeutic properties of TG4040 in combination with pegylated interfer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.